Close this search box.

Deals roundup: Novo boosts obesity manufacturing with Catalent buy


BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5

By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst

February 6, 2024 1:30 AM UTC

Novo Nordisk’s $11 billion acquisition of three fill-finish sites on two continents represents a giant step toward alleviating supply concerns around fast-selling obesity drug Wegovy semaglutide.

The two-step process began with the acquisition by Novo Holdings A/S of Catalent Inc. (NYSE:CTLT) for $63.50 per share, suggesting an enterprise value of $16.5 billion. Then, Novo Holdings sold the three sites — in Belgium, Italy and Indiana — to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO)…